KRT17 anticorps

N° du produit ABIN6295932

Cet anticorps anti-KRT17 est un anticorps Souris Monoclonal détectant KRT17 dans WB, IHC, IF et FACS. Adapté pour Humain, Rat, Boeuf (Vache), Porc et Chévre.

Aperçu rapide pour KRT17 anticorps (ABIN6295932)

Antigène: KRT17 (Keratin 17 (KRT17))

Reactivité: Humain, Rat, Boeuf (Vache), Porc, Chévre

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp KRT17 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Flow Cytometry (FACS)

Détail du produit anti-KRT17 anticorps

Fonction: Mouse anti-Human/Rat/Cow/Goat/Pig Cytokeratin 17 Antibody [Sodium Azide Free]

Specificité: Cytoplasmic

Purification: A cytoskeletal fraction of rat colon epithelium was used as the immunogen for this Cytokeratin 17 antibody.

Immunogène: A cytoskeletal fraction of rat colon epithelium was used as the immunogen for this Cytokeratin 17 antibody.

Information d'application

Indications d'application: Flow Cytometry: 0.5-1 μg/million cells in 0.1ml
Immunofluorescence: 1-2 μg/mL
Western blot: 0.5-1 μg/mL
Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT (1)
Prediluted format: incubate for 30 min at RT (2)

Restrictions: For Research Use only

Stockage

Buffer: In 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: 4 °C,-20 °C

Stockage commentaire: 2-8°C. The azide-free format should be aliquoted and stored at -20°C or colder.

Détails sur KRT17

Antigène: KRT17 (Keratin 17 (KRT17))

Autre désignation: Keratin, type I cytoskeletal 17

Sujet:

Target Description: Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IF's). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered an epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20 % of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

Gene Symbol: KRT17

ID gène: 3872

UniProt: Q04695